Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
A$ 0.16
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Strong growth
Data is available to registered users only
Data is available to registered users only
About
Argenica Therapeutics Limited engages in the research and development of a neuroprotective therapeutic drug in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate use to protect brain cells and reduce cell death during a stroke and other types of neural injuries. The company was incorporated in 2019 and is based in Nedlands, Australia.
Company Valuation
Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is underpriced on P/E.
Data is available to registered users only
Buy
Sell